SCHEMBL389901

SCHEMBL389901

O=c1[nH]cnc2ncc(Br)cc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.54
PIM3 Q86V86 2/20 0.54
CHEK1 O14757 2/20 0.54
AKT1 P31749 1/20 0.54
FLT3 P36888 1/20 0.54
IP6K1 Q92551 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 1/20 0.46
TSHR P16473 1/20 0.46
ADORA2A P29274 1/20 0.46
SLC6A4 P31645 1/20 0.46
ADRA1A P35348 1/20 0.46
XDH P47989 1/20 0.46
RAB9A P51151 1/20 0.46
BLM P54132 1/20 0.46
ALDH1A1 P00352 3/20 0.45
CDC7 O00311 1/20 0.45
CSNK2A2 P19784 1/20 0.45
CSNK2B P67870 1/20 0.45
CSNK2A1 P68400 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21895453 0.78 PARP1 (0.54) PIM1PIM3CHEK1AKT1FLT3
SCHEMBL24674303 0.74 IP6K1 (0.64) PIM1PIM3CHEK1FLT3IP6K1
SCHEMBL620396 0.72 SMN1; SMN2 (0.48) PIM1CHEK1SMN1; SMN2LMNAALDH1A1
SCHEMBL10131569 0.72 DYRK1A (0.46) PIM1PIM3CHEK1AKT1FLT3
SCHEMBL22715410 0.71 PIM1 (0.51) PIM1PIM3CHEK1AKT1FLT3
SCHEMBL22726055 0.71 PARP1 (0.55) CHEK1IP6K1RAB9AACVR1PARP1
SCHEMBL29427694 0.71 PARP1 (0.55) CHEK1IP6K1RAB9AACVR1PARP1
SCHEMBL31380182 0.70 PIM1 (0.54) PIM1PIM3CHEK1AKT1FLT3
SCHEMBL6921618 0.70 PIM1 (0.50) PIM1PIM3CHEK1AKT1FLT3
SCHEMBL182871 0.70 PIM1 (1.00) PIM1PIM3CHEK1AKT1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-05-26 US disclosed
US-12606562-B2 Pyridopyrimidines derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-04-21 US disclosed
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-11 US disclosed
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. 2025-05-22 US disclosed
US-20250066358-A1 Inhibitors of Menin-MLL Interaction BALA THERAPEUTICS, INC. 2025-02-27 US disclosed
EP-4444300-A2 INHIBITORS OF MENIN-MLL INTERACTION Bala Therapeutics, Inc. (US) 2024-10-16 EP disclosed
CN-118239931-A As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-06-25 CN disclosed
CN-114269432-B As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-05-07 CN disclosed
CN-113891745-B As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-05-07 CN disclosed
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-06 US disclosed
WO-2014055955-A1 GDF-8 INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2014-04-10 WO disclosed
US-8435985-B2 Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors MENEAR KEITH (GB) 2013-05-07 US disclosed
US-20120142673-A1 Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors KUDOS PHARMACEUTICALS LIMITED (GB) 2012-06-07 US disclosed
US-8101602-B2 Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors Kudos Pharmaceuticals, Ltd. (GB) 2012-01-24 US disclosed
US-20110124638-A1 Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors KUDOS PHARMACEUTICALS LIMITED (GB) 2011-05-26 US disclosed
US-7902189-B2 antitumor agent, anticarcinogenic agents; 7-Chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine; inhibitors of mTOR kinase ASTRAZENECA AB (SE) 2011-03-08 US disclosed
EP-2057156-A1 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS Kudos Pharmaceuticals Limited (GB) 2009-05-13 EP disclosed
US-20080194546-A1 Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors KUDOS PHARMACEUTICALS LIMITED (GB) 2008-08-14 US disclosed
US-20080081809-A1 Novel Compounds KUDOS PHARMACEUTICALS LIMITED (GB) 2008-04-03 US disclosed
WO-2008023161-A1 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS KUDOS PHARMACEUTICALS LIMITED (GB) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12606562-B2 Pyridopyrimidines derivatives as P2X3 inhibitors P2RX3, P2RX1, P2RX2 PIM1 4212/4885PIM3 3800/4885CHEK1 3460/4885
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION MLLT1, MEN1, BMI1 PIM1 1642/4885PIM3 1907/4885CHEK1 1086/4885
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX5, P2RX1 PIM1 4022/4885PIM3 2719/4885CHEK1 3989/4885
US-20120142673-A1 Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors MTOR, RICTOR, RPTOR PIM1 158/4885PIM3 432/4885CHEK1 198/4885
US-20250066358-A1 Inhibitors of Menin-MLL Interaction MLLT1, MEN1, BMI1 PIM1 1642/4885PIM3 1907/4885CHEK1 1086/4885
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 PIM1 3760/4885PIM3 3051/4885CHEK1 4011/4885
US-20110124638-A1 Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors MTOR, RICTOR, RPTOR PIM1 151/4885PIM3 418/4885CHEK1 227/4885
US-20080081809-A1 Novel Compounds SLC10A1, ABCB11, PKD1 PIM1 1377/4885PIM3 3255/4885CHEK1 1470/4885
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX1, P2RX7 PIM1 4519/4885PIM3 3990/4885CHEK1 2751/4885
US-20080194546-A1 Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors RPS6KB1, RPS6KA1, RPS3A PIM1 2999/4885PIM3 3068/4885CHEK1 1649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.